+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07225439

Phase I Study of Rituximab and Tafasitamab with Allogeneic NK Cells for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Led by Paolo Caimi, MD · Updated on 2026-09-09

15

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research focuses on people with relapsed or refractory B-cell non-Hodgkins lymphoma NHL that has not responded to at least two prior treatments. It aims to find the recommended dose of allogeneic natural killer NK cells combined with IL-2, Tafasitamab, and Rituximab for treating this condition. NK cells are experimental immune cells that can kill cancer cells and are not yet FDA-approved. The study addresses a need for new therapies as current treatments, including CAR-T cell therapy, have limitations and relapses are common. Participants will receive lymphodepleting chemotherapy followed by intravenous infusions of allogeneic NK cells, Tafasitamab, Rituximab, and Interleukin-2. The NK cells are given weekly for three weeks, with dose escalation to find the best dose. Rituximab is given once per cycle, and Tafasitamab and IL-2 are given weekly for three weeks. Each treatment cycle lasts 28 days, and participants may complete a second cycle if their disease is stable or improved after the first. During the study, participants will be monitored for safety and response to treatment over about 12 months. Assessments include tracking dose-limiting toxicities for up to 42 days, adverse events for up to 12 months, and measuring response rates on days 28 and 100. Researchers will also evaluate overall survival and event-free survival for up to a year. Participants will have regular visits for treatment and evaluation throughout the study period.

CONDITIONS

Brief Title

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Research Team

P

Paolo Caimi, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here